Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Sölétormos G, et al. Among authors: verheijen rh. Int J Gynecol Cancer. 2016 Jan;26(1):43-51. doi: 10.1097/IGC.0000000000000586. Int J Gynecol Cancer. 2016. PMID: 26588231 Free PMC article.
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study.
Hermsen BB, Olivier RI, Verheijen RH, van Beurden M, de Hullu JA, Massuger LF, Burger CW, Brekelmans CT, Mourits MJ, de Bock GH, Gaarenstroom KN, van Boven HH, Mooij TM, Rookus MA. Hermsen BB, et al. Among authors: verheijen rh. Br J Cancer. 2007 May 7;96(9):1335-42. doi: 10.1038/sj.bjc.6603725. Epub 2007 Apr 10. Br J Cancer. 2007. PMID: 17426707 Free PMC article.
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: verheijen rh. J Clin Oncol. 2005 Oct 1;23(28):6890-8. doi: 10.1200/JCO.2005.02.626. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129845 Free article.
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: verheijen rh. J Clin Oncol. 2006 Aug 1;24(22):3576-82. doi: 10.1200/JCO.2005.05.1896. J Clin Oncol. 2006. PMID: 16877724 Free article.
Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I; EORTC GCG and EORTC GCG Translational Research Group. Despierre E, et al. Int J Gynecol Cancer. 2014 Mar;24(3):468-77. doi: 10.1097/IGC.0000000000000089. Int J Gynecol Cancer. 2014. PMID: 24557434
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
van der Zee AG, Colombo N, Gitsch G, Reed N, Amant F, Cibula D, Kesic VI, Kimmig R, Lopes AD, Markowska J, Marth C, Radolakis A, Salvesen H, Vaitkiene D, Verheijen RH, Zola P. van der Zee AG, et al. Among authors: verheijen rh. Int J Gynecol Cancer. 2012 Jan;22(1):175. doi: 10.1097/IGC.0b013e3182261f15. Int J Gynecol Cancer. 2012. PMID: 22193647 No abstract available.
266 results